Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

New Software Tool Identifies Driver Genes and Pathways in Cancer Sequencing Studies

By BiotechDaily International staff writers
Posted on 03 Sep 2013
Cancer researchers have developed a software tool that enables them to identify the driver mutations that underlie the transformation of normal cells and tissues into malignancies.

Cancers are caused by the accumulation of genomic alterations. Driver mutations are required for the expression of a cancer phenotype, whereas passenger mutations are irrelevant to tumor development and accumulate through DNA replication. A major challenge facing the field of cancer genome sequencing has been identifying cancer-associated driver gene mutations.

Investigators at the Medical College of Wisconsin (Milwaukee, USA) have described a powerful and flexible statistical framework for identifying driver genes and driver signaling pathways in cancer genome-sequencing studies. Biological knowledge of the mutational process in tumors was fully integrated into their statistical models, which included such variables as the length of protein-coding regions, transcript isoforms, variation in mutation types, differences in background mutation rates, the redundancy of genetic code, and multiple mutations in one gene.

A detailed description of the software tool, which was nicknamed DrGaP—for Driver Genes and Pathways—was published in the August 15, 2013, online edition of the American Journal of Human Genetics.

"DrGaP is immediately applicable to cancer genome sequencing studies and will lead a more complete identification of altered driver genes and driver signaling pathways in cancer," said senior author Dr. Pengyuan Liu, associate professor of physiology at the Medical College of Wisconsin. "Biological knowledge of the mutation process is fully integrated into the models, and provides several significant improvements and increased power over current methods."

Related Links:
Medical College of Wisconsin



view channel
Image: A new catalyst that improved the sensitivity of the standard PSA ELISA test by about 110-fold was made of palladium nanocubes coated with iridium (Photo courtesy of Dr. Xiaohu Xia, Michigan Technological University).

Peroxidase Mimic Outperforms Natural Horseradish Peroxidase in ELISA Test

A test-of-concept study demonstrated that a synthetic catalyst that mimics the action of horseradish peroxidase (HRP) could increase the sensitivity of a colorimetric enzyme-linked immunosorbent assay... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more


view channel

Biopharmaceutical Partners Seek Alternatives to Glucocorticoid Steroid Drugs

Collaboration between American and Japanese biopharmaceutical companies is expected to lead to the development of a new class of small molecule drugs for treatment of hematological and inflammatory diseases. Gencia LLC (Charlottesville, VA, USA) and Takeda Pharmaceutical Company Ltd. (Osaka, Japan) announced the formation... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.